FDA requires eye-risk warning labels on GLP-1 drugs such as Ozempic
Published November 11, 2026 · Updated November 11, 2026 · 4 sources
The FDA is requiring GLP-1 drug labels to carry a warning on NAION, a rare eye condition linked to vision loss. Novo Nordisk and Eli Lilly make drugs named.
The exposed companies and what ATLAS says about each
Price change between the last close before the event and the latest available close. It is a coincidence in time, not a cause-and-effect relationship.
Maker of Ozempic and Wegovy, both named in the FDA's new eye-risk warning label requirement. · Healthcare
Novo Nordisk makes Ozempic and Wegovy, both named in the FDA's new label requirement [1][3]. Its close was $40.70 on November 10 and $40.48 on November 11, down 0.54%, a coincidence in time between two closes and not a demonstrated effect of the news. Its dividend yield is 4.58%.
Price between closes
$40.70 → $40.48Close of November 10 and November 11
Fair value (ATLAS)
$83.46Fair range: $70.75 to $106.94The price ($40.48) is 51.5% below that figure.
Chance of a rise in 1 month
50%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $38.07 and $43.09; 9 in 10, between $34.11 and $48.08.
Maker of Zepbound, a GLP-1 drug named in the FDA's new eye-risk warning label requirement. · Healthcare
Eli Lilly makes Zepbound, a GLP-1 drug named in the FDA's label requirement [2][3]. Its close was $1,432.29 on November 10 and $1,423.66 on November 11, down 0.60%, a coincidence in time between two closes and not a demonstrated effect of the news. Its dividend yield is 0.47%.
Price between closes
$1,432.29 → $1,423.66Close of November 10 and November 11
Fair value (ATLAS)
$810.10Fair range: $663.02 to $1,034.88The price ($1,423.66) is 75.7% above that figure.
Chance of a rise in 1 month
50%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $1,337.25 and $1,516.50; 9 in 10, between $1,196.15 and $1,695.38.
Recent results (EPS)
Oct 297.48 actual vs 5.38 est.Beat expectations
Aug 58.38 actual vs 6.58 est.Beat expectations
Apr 308.55 actual vs 6.79 est.Beat expectations
Feb 47.54 actual vs 6.91 est.Beat expectations
Dividend
0.47% dividend yieldNext ex-dividend date: November 13, 2026 · 6.69 $ over the last 12 months
S&P 500 between the same closes (November 10 and November 11): 7,520.93 → 7,618.18 points, +1.29%.
What happened
The US Food and Drug Administration is requiring warning labels on GLP-1 drugs, including Ozempic, Wegovy and Zepbound, over a rare eye condition tied to vision loss [1]. Novo Nordisk and Eli Lilly make drugs named in the requirement, so both are covered below.
The FDA now requires warning labels on Ozempic, Wegovy and other GLP-1 drugs over a rare eye condition tied to vision loss [1]. CNN's headline says the agency ordered new eye risk warnings for Ozempic and Zepbound [2].
According to The Guardian, the FDA announced on Monday that all GLP-1 medications must include information about the potential risk of nonarteritic anterior ischemic optic neuropathy, known as NAION. The drugs named include Novo Nordisk's Ozempic and Wegovy, Eli Lilly's Mounjaro and Zepbound, and Sanofi's Soliqua [3].
NAION is a rare condition involving a sudden reduction of blood flow to the optic nerve, resulting in acute, painless, decreased vision in one eye, including permanent vision loss, the FDA warned [3]. Common risk factors include diabetes, smoking, hypertension and hypercholesterolemia [3].
The Guardian reports that NAION is the most common cause of acute optic nerve injury in people over 50, with an annual average of 2.3 to 10.2 cases out of 100,000 people above that age. It also reports that there is for now no treatment to reverse vision loss from NAION [3].
What ATLAS data show
ATLAS model estimates put Novo Nordisk's fair value at $83.46, within a range of $70.75 to $106.94. Its latest close is 51.50% below that estimate. For Eli Lilly, the model estimate is $810.10, within a range of $663.02 to $1,034.88, and its latest close is 75.74% above it. These are model estimates, not promises, and they say nothing about how the label change will affect either company.
Two prices moving over the same period do not show that one caused the other; the S&P 500 rose 1.29% between the same two closes, from 7,520.93 to 7,618.18 points. The figures come from closing prices on November 10 and November 11 and may change.
What you get with ATLAS
Fair value of each company, with its range, against today's price.
Chance of a rise in 1 month and the normal price range, from a calibrated model.
Earnings: next date, estimated EPS and surprise history.
Dividends and alerts by email when a company reports.
It is nonarteritic anterior ischemic optic neuropathy, a rare condition involving sudden reduced blood flow to the optic nerve. It can cause painless loss of vision in one eye, including permanent loss [3].
Which drugs are covered by the requirement?
The FDA is requiring all GLP-1 medications to carry the warning. The Guardian names Ozempic, Wegovy, Mounjaro, Zepbound and Soliqua [3].
Did Novo Nordisk and Eli Lilly shares fall on the news?
Novo Nordisk closed down 0.54% and Eli Lilly down 0.60% between November 10 and November 11. This is a coincidence in time and does not show the news caused it.
Closing prices, fair value, probabilities, earnings and dividends: ATLAS own data as of November 11, 2026. How we calculate fair value.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
ATLAS Signals, every week
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy
ATLAS